Please assess the completion status of the following clinical trial:

Trial Title: Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ranging from 20 - 80 years~2. Body mass index (BMI) of 20-38 to include the typical obese OSA patients and avoid the practical difficulties in blood drawing from the massively obese~3. Hypertension with blood pressures \> 140/90 but less than 180/105 mmHg.~4. Apnea-hypopnea index above 10~Exclusion Criteria:~1. Receiving medications other than anti-hypertensives known to influence the sympathetic nervous system, sleep medicines (including heavy alcohol use) or drugs with adverse interactions with study medication.~2. Women who have premenstrual syndrome, or those who are pregnant or capable of pregnancy and unwilling to use effective non-hormonal contraception~3. Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in order to minimize confounding effects of other sleep disorders~4. Have apneas which are primarily central~5. Have sleep fragmentation caused by syndromes such as chronic pain or movement disorders~6. Have diseases such as asthma or chronic obstructive pulmonary disease that compromises respiration.~7. Have known coronary or cerebral vascular disease, history of arrhythmias, cardiomyopathy, history of psychosis, current alcohol or drug abuse.~8. Have any contraindications to any study materials, such as heart block.~9. Have secondary hypertension~10. Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria or electrolyte disorders.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, Guanfacine, Hydrochlorothyazide (Type: EXPERIMENTAL): Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
- Placebo, Hydrochlorothyazide, Guanfacine (Type: EXPERIMENTAL): Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).